Topical Hair Loss Treatments Beyond Minoxidil

Putting something on the scalp instead of swallowing it changes three things: how much of it reaches the follicle, how much of it reaches the rest of you, and which regulatory category it lands in. The third one is why the topical shelf is so much more confusing than the prescription pad, and it is the thing this page is about.

The approved topical is minoxidil, and its position is not in dispute. What sits around it is a mixture of compounded prescriptions, antifungals used for something their label does not name, and cosmetics — and those three are not interchangeable, however similar the bottles look.

The one that is approved, and what its own label limits

Topical minoxidil is sold over the counter as a hair regrowth treatment. Its drug-facts label names regrowth on the top of the scalp — the vertex — as the use it is for, and states that it is not intended for frontal baldness or a receding hairline.

That sentence is on the carton and is almost never on the marketing, and it matters for anyone whose concern is the front of the hairline rather than the crown: the approved use is the area that was tested. What strength to buy, how to apply it and whether to use it at all are questions for the label and a pharmacist, and this page does not answer them.

Compounded topicals: real trials, no approved label

Topical finasteride is the most-discussed of these, and its status is unambiguous. In an alert dated 22 April 2025, the FDA stated that there is no FDA-approved topical formulation of finasteride, that compounded topical finasteride products do not have FDA-approved labelling, and that it had received adverse-event reports naming erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido and testicular pain — most of which, the agency noted, persisted after people stopped. Some consumers reported being incorrectly assured that a topical posed no risk — and the same alert says absorption through the skin into the bloodstream is expected, which is the plainest available answer to the assumption that putting a drug on a scalp keeps it there.

At the same time, topical finasteride arms appear in the pooled randomised evidence: a 2025 network meta-analysis of monotherapies for male androgenetic alopecia included topical finasteride preparations alongside the oral drug, topical and oral minoxidil and oral dutasteride.

Both of those things are true at once, and that is exactly the situation the grading rule on this site is built for. The trials are real, the approval does not exist, and the grade takes the worse answer. Compounded mixtures also vary between pharmacies, which means no single published label describes what is in a particular bottle — a prescriber is the only person who can tell you what yours contains.

Antifungals, and the other comparators with trials

The same 2025 network meta-analysis carried seven non-conventional, over-the-counter agents alongside the conventional monotherapies: topical ketoconazole, a marine complex, topical melatonin, procyanidin, rosemary, topical saw palmetto and watercress. Its stated conclusion was that it confirmed the efficacy of the conventional monotherapies, and that it provided guidance on the relative efficacy of some alternative agents — naming topical melatonin and rosemary oil — compared with them.

That is a carefully worded finding and it deserves to be repeated carefully. Being included as a comparator in a pooled analysis is more than most of the shelf can claim; it is not an approval, the underlying trials are smaller than the conventional ones, and the authors noted that many of the alternative-agent trials involved smaller samples and that the analysis focused on a single time point.

Ketoconazole is worth a line of its own because its position is so often overstated. It is an antifungal, sold for dandruff and seborrhoeic dermatitis, not for pattern hair loss. It has controlled-trial evidence as a comparator and no approval for this use, which is why this site grades it in the middle of the index rather than near the top — and why a generic version bought as a shampoo is, on the evidence, the same proposition as an expensive one.

Cosmetics, which are doing a different job

The third group is the largest by shelf space: thickening shampoos, volumising sprays, scalp serums with proprietary complexes. The FDA's own explainer states that cosmetic products and ingredients, and their labelling, do not require FDA approval.

Most of these products are honest about what they do if you read the claim rather than the imagery. Coating a hair shaft so it reflects more light and sits further from its neighbours genuinely changes how hair looks. It is not regrowth, no controlled trial shows regrowth from it, and a cosmetic that claimed to treat a condition would be making a drug claim. This site grades that group in its lowest tier, which is a statement about evidence rather than an accusation of fraud.

How to place any topical in about three questions

1. What is the active ingredient, by name? Not the brand, not the complex, the molecule. If the answer is hard to find, that is the answer.
2. Which category is it in? Approved over-the-counter drug, compounded prescription, antifungal used off its label, or cosmetic. Each one implies a different amount of scrutiny.
3. What has been published about the ingredient, and by whom? A pooled analysis of randomised trials by authors with nothing to sell is a different animal from a study funded by the seller, which is a different animal again from a page of testimonials.

Those three questions are two thirds of what the index of hair-loss treatments does, and the words in question two are the ones most often used loosely — which is why what approved, cleared and unapproved actually mean is the page to read next.